Condition: Multiple Myeloma · Sponsor: SCRI Development Innovations, LLC
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
This description comes directly from the study's public registry record.
Sarah Cannon Development Innovations, LLC · 1-844-710-6157 · SCRI.InnovationsMedical@scri.com
Always discuss trial participation with your own doctor first.
| Arizona Oncology Associates | Tucson, Arizona, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Rocky Mountain Cancer Center | Denver, Colorado, United States | Recruiting |
| Medical Oncology Hematology Consultants | Newark, Delaware, United States | Recruiting |
| Florida Cancer Specialists | Lake Mary, Florida, United States | Withdrawn |
| Maryland Oncology Hematology | Columbia, Maryland, United States | Recruiting |
| Minnesota Oncology Hematology | Minneapolis, Minnesota, United States | Recruiting |
| Virginia Oncology Associates | Elizabeth City, North Carolina, United States | Recruiting |
| Oncology Hematology Care | Cincinnati, Ohio, United States | Recruiting |
| Oncology Associates of Oregon | Eugene, Oregon, United States | Recruiting |
| TriStar Bone Marrow Transplant | Nashville, Tennessee, United States | Recruiting |
| Vanderbilt- Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05972135